Patibandla Mohana Rao, Thotakura Amit Kumar, Rao Marabathina Nageswara, Addagada Gokul Chowdary, Nukavarapu Manisha Chowdary, Panigrahi Manas Kumar, Uppin Shantiveer, Challa Sundaram, Dandamudi Srinivas
Department of Neurosurgery, Nizam's Institute of Medical Sciences, Hyderabad, India.
Department of Neurosurgery, NRI Medical College, Mangalagiri, Guntur, Andhra Pradesh, India.
Asian J Neurosurg. 2017 Jan-Mar;12(1):78-81. doi: 10.4103/1793-5482.145112.
Giant-cell tumor (GCT) involving the skull base is rare. Sphenoid bone is the most commonly involved bone followed by petrous temporal bone. Histopathology and radiological features of these lesions are similar to GCT involving bone elsewhere. Unlike other sites, skull base is not an ideal site for the radical surgery. Hence adjuvant treatment has pivotal role. Radiation therapy with intensity-modulated radiation therapy, stereotactic radiosurgery or chemotherapy with adriamycin are promising as described in some case reports. Bisphosphonates showed good control in local recurrence. studies with Zolendronate loaded bone cement and phase 2 trials of Denosumab showed hopeful results, may be useful in future.
累及颅底的骨巨细胞瘤(GCT)较为罕见。蝶骨是最常受累的骨骼,其次是颞骨岩部。这些病变的组织病理学和放射学特征与其他部位的骨巨细胞瘤相似。与其他部位不同,颅底并非根治性手术的理想部位。因此,辅助治疗起着关键作用。如一些病例报告所述,调强放射治疗、立体定向放射外科放疗或阿霉素化疗等放射治疗前景良好。双膦酸盐在控制局部复发方面表现良好。载有唑来膦酸的骨水泥研究以及地诺单抗的2期试验显示出了有希望的结果,未来可能会有用。